Detected ·
Delix Therapeutics
$100MSeries C
Delix Therapeutics closed an oversubscribed $100M Series C, led by Johnson & Johnson Innovation JJDC and SV Health Investors' Dementia Discovery Fund, to advance zalsupindole and its neuroplastogen pipeline.
- Website
- —
- linkedin.com/company/76400524
- Amount
- $100 000 000 USD
- Stage
- Series C
- Event
- Funding round
- Detected
- 2026-11-11 12:13:55 UTC
- Signal ID
- a336f9c9-3254-4587-b800-ce243f9408bb
As the API returns it
{
"id": "a336f9c9-3254-4587-b800-ce243f9408bb",
"created_at": "2026-11-11T12:13:55.931071Z",
"company_name": "Delix Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/76400524",
"event_type": "funding",
"funding_amount": 100000000,
"funding_currency": "USD",
"funding_stage": "series_c",
"message": "*Delix Therapeutics closed an oversubscribed $100M Series C, led by Johnson & Johnson Innovation JJDC and SV Health Investors' Dementia Discovery Fund, to advance zalsupindole and its neuroplastogen pipeline.*"
}